The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
MOMENTUM: How might momelotinib change the treatment for cytopenic patients with MF?
Featured:
Ruben A. MesaDuring the ASCO 2022 Annual Meeting, the MPN Hub was pleased to speak to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, How might momelotinib change the treatment for cytopenic patients with MF?
MOMENTUM: How might momelotinib change the treatment for cytopenic patients with MF?
Mesa begins by discussing data presented at ASCO 2022 from the MOMENTUM study, and the mechanism of action of momelotinib. Mesa talks about the primary endpoints of the study, and the reduction in splenomegaly symptoms and anemia.
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?